poisar

Stocks · News reference

Seres Therapeutics To Present Preclinical Data Supporting Development Of SER-428, Investigational Oral Liquid LBP To Reduce Risk Of Bloodstream Infections In Critically Ill Patients, At IDWeek 2026

Benzinga Newsdesk

Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tubeSER-428 significantly reduced gastrointestinal

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MCRB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

    Seres Therapeutics announced preclinical data for SER-428, an investigational live biotherapeutic designed to reduce bloodstream infections in critically ill patients. The novel oral liquid formulation showed up to 1,000-fold reduction of pathogenic bacteria in preclinical models and builds on positive results from SER-155. The company is designing a Phase 1b trial in collaboration with Columbia University, with further development pending funding.

    MCRB